Press Release

Molecular Partners to Present at the 17th Annual Meeting of Bio€quity Europe 2016 in Copenhagen

Zurich-Schlieren, May 09, 2016. Molecular Partners AG (ticker: MOLN) today announced that it will present at the 17th Annual Meeting of Bio€quity Europe in Copenhagen on Tuesday, May 10, 2016 at 2:00 PM CET.  The presentation will be hosted by Dr. Patrick Amstutz, COO of Molecular Partners.

A copy of the presentation handout will be made available on the company’s website under the Investors section.


About Molecular Partners AG

Molecular Partners AG is a clinical-stage biopharmaceutical company that is developing a new, class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors. For more information regarding Molecular Partners AG, go to:


For further details, please contact:

Dr. Christian Zahnd, CEO
Tel: +41 (0) 44 755 77 00

Andreas Emmenegger, CFO
Tel: +41 (0) 44 755 77 00

Rolf Schläpfer
Tel: +41 (0) 43 344 42 42